Syros Pharmaceuticals Q4 EPS $(2.22) Misses $(1.14) Estimate, Sales $386.00K Miss $2.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Syros Pharmaceuticals (NASDAQ:SYRS) reported a significant miss in both earnings and revenue for Q4. EPS was $(2.22), missing estimates by 94.74%, and sales were $386.00K, missing estimates by 80.70%. This represents a drastic decrease in earnings and a significant increase in sales from the same period last year.
March 27, 2024 | 11:31 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Syros Pharmaceuticals reported a significant miss in Q4 earnings and revenue, with EPS at $(2.22) and sales at $386.00K, missing estimates substantially.
The substantial miss in both earnings per share and revenue compared to analyst estimates indicates a significant underperformance by Syros Pharmaceuticals. This underperformance, especially being a 1205.88% decrease in earnings from the previous year, is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100